Skip to main content

RNAi / siRNA Deal Benchmarks in Ophthalmology

Median Upfront
$698M
Range: $384M - $998M
Total Deal Value
$3.3B
Range: $2.1B - $4.4B
Royalty Rate
9.9% - 19.9%
Tiered up to 23.9%
Dev Milestones
$518M
Range: $350M - $688M
Model Your Deal

Market Analysis

RNAi / siRNA therapies in ophthalmology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in ophthalmology is $698M, with total deal values reaching $3.3B. Development milestones average $518M, while regulatory milestones contribute $647M.

The ophthalmology rnai / sirna landscape is characterized by moderate competitive intensity concentrated in retinal disease and dry eye. Gene therapies for inherited retinal diseases, extended-duration intravitreal agents, and topical biologics are expanding the opportunity set. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna ophthalmology deals range from 9.9% to 19.9% at the base tier, with tiered escalation reaching 13.9%-23.9% on blockbuster sales. Commercial milestones averaging $1.4B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna ophthalmology licensing deal?
Based on our analysis, Phase 2 rnai / sirna licensing deals in ophthalmology average $698M in upfront payments, with a range of $384M to $998M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for rnai / sirna ophthalmology transactions?
The median total deal value for Phase 2 rnai / sirna assets in ophthalmology is $3.3B, ranging from $2.1B to $4.4B. This includes development milestones ($518M), regulatory milestones ($647M), and commercial milestones ($1.4B).
What royalty rates are standard for rnai / sirna deals in ophthalmology?
Base royalty rates for rnai / sirna ophthalmology transactions range from 9.9% to 19.9%, with tiered escalations reaching 13.9%-23.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in rnai / sirna ophthalmology deals?
RNAi / siRNA ophthalmology deals allocate approximately 79% of total deal value to milestones. Development milestones ($518M) make up the largest share, followed by commercial milestones ($1.4B) and regulatory milestones ($647M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Ophthalmology

View

Monoclonal Antibody in Ophthalmology

View

RNAi / siRNA in Oncology

View

RNAi / siRNA in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included